Status:
COMPLETED
Study to Assess Safety and Quality of Life of Patients Using Biojector Versus Needles for Fuzeon Administration
Lead Sponsor:
Canadian Immunodeficiency Research Collaborative
Collaborating Sponsors:
Roche Pharma AG
Conditions:
Human Immunodeficiency Virus
Eligibility:
All Genders
18-50 years
Phase:
PHASE2
Brief Summary
Hypothesis: Patients using enfuvirtide with the Biojector have an improved quality of life, greater satisfaction, and fewer adverse events compared with using the standard needle.
Detailed Description
This study is a "N of one" trial where the patient is their own control. We will provide the quality of life questionnaire, the MOS-HIV questionnaire; ISR questionnaire and a satisfaction questionnair...
Eligibility Criteria
Inclusion
- Patients who have taken enfuvirtide for at least one month
Exclusion
- Patients with hemophilia
Key Trial Info
Start Date :
May 1 2005
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
September 1 2008
Estimated Enrollment :
337 Patients enrolled
Trial Details
Trial ID
NCT00333736
Start Date
May 1 2005
End Date
September 1 2008
Last Update
June 5 2012
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Maple Leaf Medical Clinic
Toronto, Ontario, Canada, M5B 1L6